Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. Reply

Affiliations

¹ University of California, San Francisco, San Francisco, CA dennis.black@ucsf.edu.
² University of Sheffield, Sheffield, United Kingdom.
³ Kaiser Permanente Southern California, Pasadena, CA.

Comment

Dennis M Black et al. N Engl J Med. 2020.

. 2020 Nov 26;383(22):2189-2190.

doi: 10.1056/NEJMc2029828.

¹ University of California, San Francisco, San Francisco, CA dennis.black@ucsf.edu.
² University of Sheffield, Sheffield, United Kingdom.
³ Kaiser Permanente Southern California, Pasadena, CA.

No abstract available

Comment on

Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, Dell RM, Adams AL. Black DM, et al. N Engl J Med. 2020 Aug 20;383(8):743-753. doi: 10.1056/NEJMoa1916525. N Engl J Med. 2020. PMID: 32813950 Free PMC article.
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
Ueda M, Kami M. Ueda M, et al. N Engl J Med. 2020 Nov 26;383(22):2188. doi: 10.1056/NEJMc2029828. N Engl J Med. 2020. PMID: 33252880 No abstract available.
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
Ott SM, Heckbert SR. Ott SM, et al. N Engl J Med. 2020 Nov 26;383(22):2188-2189. doi: 10.1056/NEJMc2029828. N Engl J Med. 2020. PMID: 33252881 No abstract available.
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
Garton M. Garton M. N Engl J Med. 2020 Nov 26;383(22):2189. doi: 10.1056/NEJMc2029828. N Engl J Med. 2020. PMID: 33252882 No abstract available.